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Background: We compared indomethacin therapy with the more aggressive approaches of anti-cancer chemotherapy and 
surgery in the treatment of isolated Langerhans cell histiocytosis (LCH) of bone in children. 
Methods: Comparisons were made with respect to healing of the lesion without recurrence, time to radiological healing of the 
lesion, time to functional recovery, and complications related to treatment. 
Results: Complete radiologic healing of the lesion (mean, 15.3 months) and functional recovery (mean, 5.6 months) were observed 
in all patients treated with either approach. No signiﬁ  cant differences were noted in the time to complete radiologic healing or the 
time to functional recovery between the two groups. There were no recurrences with either approach until the last follow-up (mean, 
56 months). Complications were common with anti-cancer chemotherapy, but indomethacin was well-tolerated. 
Conclusions: Indomethacin seems to be effective for treating isolated LCH of bone in children. Hence, morbidities associated 
with aggressive treatment approaches such as anti-cancer chemotherapy or surgery can be avoided.
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Langerhans cell histiocytosis (LCH) encompasses a 
group of histologically similar disorders, characterized by 
infiltration of tissues by cells of monocyte-macrophage 
lineage.
1,2)  The clinical forms of LCH vary widely, from 
generalized and fulminant forms to localized and curable 
forms.
3,4) Isolated LCH of bone, also known as eosinophilic 
granuloma, is one of the mildest forms of the disease, 
with satisfactory results being reported especially in 
children.
5) Many diff  erent approaches have been used for 
the treatment of isolated LCH of bone in children,
6,7) from 
modest approaches such as simple observation and steroid 
injections
8) to aggressive approaches such as surgery, 
anti-cancer chemotherapy, and radiation therapy.
5,9,10) 
A treatment approach that carries a lower chance of 
complications while ensuring a successful cure is desirable 
in this cohort of patients.
Indomethacin is a nonsteroidal anti-inflammatory 
drug that inhibits cyclo-oxygenase, thereby blocking the 
arachidonic acid-prostaglandin pathway. Prostaglandins 
(PG) have been implicated in the pathogenesis of 
LCH. Purified LCH cells from bony lesions produce 
interleukin 1 and PGE2 in vitro,
11) and LCH cells in cases 
of disseminated LCH have been shown to produce PGD2 
and thromboxane.
12) Th   e use of indomethacin in treating 
various forms of LCH has been previously reported.
13,14) 
However, no study comparing indomethacin with other 
treatment modalities in isolated LCH of bone has been 
reported.
We fi rst sought to determine if indomethacin ther-64
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Age (years) 8 6
Gender (M / F) 6 / 6 12 / 9
Location
    Clavicle 16.6% (2)* 13% (3)
    Scapula 0% (0) 10% (2)
    Humerus 16.6% (2) 10% (2)
    Radius  0% (0) 10% (2)
    Pelvis 16.6% (2) 10% (2)
    Femur  25% (3) 24% (5)
    Tibia 25% (3) 13% (3)
    Fibula 0% (0) 10% (2)
Average FU (months) 76 43
*Numbers in the parentheses represent the number of cases.
  Table 1.  Comparison of Clinical Presentation of the Two Groups
apy induces complete healing in isolated LCH of bone 
in children. We also sought to determine if indomethacin 
therapy is comparable to anti-cancer chemotherapy or 
surgery with respect to the time to radiological healing of the 
lesion, the time to functional recovery, and complications 
related to treatment.
METHODS
We reviewed the records of 85 patients with histologically 
proven LCH who had been managed in the authors’ 
institution since 1988. Thirty-three patients who met 
the following criteria were included in the study: 1) 
histological diagnosis of LCH; 2) single bone involvement 
excluding lesions of skull, spine, or facial bones; 3) under 
15 years of age; 4) no extraskeletal involvement. There 
were 18 boys and 15 girls, and the average age at the time 
of diagnosis was 6.7 years (range, 1 to 14 years). Eight 
diff  erent bones were involved (femur 8, clavicle 5, tibia 6, 
humerus 4, pelvis 4, scapula 2, fibula 2, radius 2). Most 
patients presented with pain or limping. 
Biopsies were performed in all patients (incisional 
in 21, excisional in 8, and percutaneous in 4). The diag-
nosis of LCH was based on light microscopy findings of 
proliferation of histiocytes with eosinophilic cytoplasm, 
often associated with multinucleated giant cells. Im-
munochemical staining with CD1a or S-100 was per-
formed in difficult-to-diagnose cases. Bone scans were 
performed to identify possible involvement of multiple 
bones. No patient had multiple osseous lesions or 
extraskeletal involvement.
Most of the patients treated in the early period of 
this series were managed with anticancer chemotherapy 
or excisional surgery. Indomethacin, a non-steroidal 
anti-inflammatory drug (NSAID), has been used in this 
group of patients at our institution since the mid-1990s. 
Th   erefore, patients in the current series were categorized 
into two groups: an aggressive treatment group (12 
patients) in which patients were treated with excisional 
surgery, anti-cancer chemotherapy, or a combination of 
both; and a modest treatment group (21 patients) in which 
patients were treated with indomethacin. There were 
no noteworthy differences in age, gender ratio, or lesion 
locations between the aggressive treatment group and the 
modest treatment group (Table 1).
Four patients in the aggressive treatment group 
were treated with anti-cancer chemotherapy, 5 patients 
were treated with surgery, and 3 patients were treated 
with surgery followed by chemotherapy. Excisional 
curettage of the lesion and bone graft  ing were performed 
in 3 patients. Internal fi  xation was not performed in any 
patient. The anti-cancer chemotherapy regimen was as 
follows: 12 weeks of induction chemotherapy consisting of 
intravenous vinblastine (starting dose 0.15 mg/kg/week, 
weekly dose escalation of 0.5 mg), oral methotrexate (10 
mg/m
2/week), and oral cyclophosphamide (100 mg/m
2/
week), followed by maintenance chemotherapy consisting 
of oral 6-mercaptopurine (50 mg/m
2/day), methotrexate 
(10 mg/m
2/week), and cyclophosphamide (100 mg/m
2/
week). Maintenance chemotherapy was continued for one 
year unless side effects prevented completion. Patients 
were followed up weekly during the induction period and 
monthly during the maintenance period with complete 
blood counts and plain radiographs of their respective 
lesions. Bone scans were examined every 2-3 months 
during the treatment period. Th   e average total duration of 
chemotherapy was 13.1 months (range, 9 to 15 months). 
In the modest treatment group, indomethacin 
was used in 21 patients. A daily dose of 1-2.5 mg/kg of 
indomethacin was administered for an average of 7.7 
months (range, 5 to 12 months). Patients were followed 
up with monthly plain radiographs, as well as bone 
scans every 2-3 months, during the course of treatment. 
Indomethacin was discontinued based upon the complete 
relief of symptoms and definitive progressive healing of 
the lesions on serial bone scans and radiographs.
Patients were followed up with plain radiographs 65
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and bone scans every 2-3 months aft  er the completion of 
treatment. Healing of the lesions was determined using 
the radiological criteria of the Children’s Cancer Study 
Group.
15) A complete response was defined as complete 
radiographic disappearance of the lesion. A partial 
response was defi  ned as at least 50 percent reduction in the 
lesion size and no appearance of new lesions. No response 
was defined as no disease improvement, a recurrence, 
or the development of a new systemic or osseous lesion. 
Functional recovery was based on the patient’s return to 
a pain-free state with normal use of the affected part.
5) 
“Pain-free” means the patient did not complain of any 
subjective pain, and “normal use of the affected part” 
means the motor power and range of motion of the 
aff  ected part were the same as those in the unaff  ected part. 
Th   e average follow-up duration was 56 months (range, 12 
to 192 months).
All statistical analysis was performed with SPSS 
soft  ware ver. 12.0 (SPSS Inc., Chicago, IL, USA). Student’s 
t-test was used to compare the time to radiological and 
functional recovery between the aggressive treatment 
group and the modest treatment group. p values less than 
0.05 were considered statistically signifi  cant.
RESULTS
Complete radiologic healing was observed in all patients 
in an average of 15.3 months (range, 5 to 36 months) (Fig. 
1). Complete functional recovery and symptomatic relief 
were achieved in an average of 5.6 months (range, 1 to 19 
months). Th   ere were no signifi  cant diff  erences between the 
two groups with respect to the time to complete radiologic 
response or the time required to return to a pain-free state 
with normal use of the aff  ected part (Table 2). No patients 
had recurrence or developed new systemic or osseous 
lesions until the last follow-up visit. No patients developed 
new symptoms, such as pain or limping during follow-up. 
Furthermore, we noted no new lesions in x-rays or bone 
scans. 
Complications related to anti-cancer chemotherapy 
were common, with all 7 patients who underwent che-
motherapy experiencing one or more complications. 
Neutropenia that necessitated cessation of treatment was 
observed in 6 patients, all of whom recovered aft  er 1 to 2 
weeks. Oral mucositis and epigastric pain were observed 
in 2 patients each. Vomiting was observed in 2 patients. 
Indomethacin was well-tolerated in all patients, except for 
one, who experienced temporary dizziness that resolved 
spontaneously. Pathologic fractures were observed in two 
patients, both of whom had lesions of the femur. One 
patient who was two months into indomethacin treatment 
had a fracture of the femoral shaft and was treated 
successfully with closed reduction and external fixation. 
Another patient suffered from a fracture of the femoral 
Fig. 1. An illustrative case of isolated 
LCH of radius in a 5-year-old boy treated 
with indomethacin. (A) A destructive 
lesion of the radius is seen. (B) Radio-
graphs made 3 months after treatment 
shows progressive healing of the lesion. 
(C) Radiographs made 15 months after 
treatment demonstrates the complete 
disappearance of the lesion and remod-
eling of the bone.66
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Aggressive 
group (n = 12)
Modest 
group (n = 21) p value
Radiologic
  Complete response 100% 100% NC
  Time to complete  
   response (months) 17.1 (SD:8.89) 14.5 (SD:6.47) p = 0.325
Functional
  Functional recovery 100% 100% NC
  Time to recovery (months) 6.2 (SD:3.52) 5.9 (SD:3.51) p = 0.732
NC: Not calculable.
  Table 2.  Radiological and Functional Results of the Two Groups in a previous study.
13) Indomethacin is a nonsteroidal anti-
infl  ammatory drug that inhibits cyclo-oxygenase, thereby 
blocking the arachidonic acid-prostaglandin pathway. 
Successful use of intralesional steroids has been reported 
in the setting of localized LCH,
18,19) and the mechanism of 
action is presumed to be inhibition of prostaglandins.
20) 
Whether indomethacin infl  uences the disease process or 
simply acts as an analgesic remains unclear. 
Munn et al.
13) reported the initial experience with 
indomethacin in 10 LCH patients. Six patients had single-
system bone disease, and 4 had multi-system disease 
involving the bony skeleton and other organs. All 6 
patients with single-system bone disease had complete 
responses to treatment, defi  ned as complete relief of pain. 
Two pathological fractures occurred in patients with 
femur lesions, one each in the modest treatment group 
and in the aggressive treatment group. Th   e small number 
of pathologic fractures makes comparison of the incidence 
of pathologic fractures between the two groups difficult. 
However, appropriate protective measures should be taken 
if the lesion is located in a weight-bearing area and poses a 
risk of pathologic fracture.
9) 
Th   ere are several limitations to this study. First, the 
study was performed in a relatively small, nonrandomized, 
retrospectively selected group of patients. Prospective 
comparison in a larger number of patients is desirable to 
establish the role of indomethacin in isolated LCH of bone, 
although the infrequency of the condition would make 
such a study difficult to perform. Secondly, the follow-
up period was significantly shorter in the group treated 
with indomethacin. Long-term eff  ects of indomethacin in 
children could be clarifi  ed with longer follow-up.
In conclusion, indomethacin seems to be effective 
for treating isolated LCH of bone in children. Morbidities 
associated with aggressive treatment approaches such 
as anticancer-chemotherapy or surgery may be avoided 
through the use of indomethacin instead.
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shaft   4 months aft  er excisional curettage and was treated 
successfully with a hip spica cast.
DISCUSSION
LCH entails a disease spectrum including systemic entities 
such as Hand-Schuller-Christian disease and Letter-Siwe 
disease, and treatment modalities used for isolated LCH 
of bone have been variable. Satisfactory results have been 
reported for various treatment modalities, giving rise 
to the hypothesis that isolated LCH of bone is a benign 
pathophysiologic process. Eosinophilic granuloma of 
the spine is known to resolve spontaneously with time in 
children, and surgery is usually not required.
16,17) In view 
of the possibility of spontaneous regression, less invasive 
forms of treatment with lower rates of complications are 
desirable. Our results support this approach. This study 
compared the results obtained with modest treatment 
modalities-namely indomethacin-with those obtained with 
aggressive treatment modalities, such as chemotherapy or 
surgery. All patients achieved complete bony healing and 
functional recovery in a similar time period. There were 
no local recurrences at the fi  nal follow-up visit.
Th   e precise mechanism of action of indomethacin in 
LCH has not been determined. In vitro studies have dem-
onstrated production of prostaglandins in isolated LCH 
cells,
11,12) providing the basis for the use of indomethacin 
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